Itamar Medical Funds Clinical Study to Evaluate Potential Impact of CPAP Therapy to Patients with COVID-19 - Seite 2

“This clinical study builds on Itamar Medical’s established legacy of generating and advancing science and research that allows our WatchPAT technology to improve health outcomes,” said Dr. Jennifer Cook, Global Medical Director of Itamar Medical and a critical care physician. “We are very pleased to be working with Dr. Shah and the team, including Drs. Indu Ayappa, David Rapoport and Ms. Samira Khan at Mount Sinai, to evaluate the potential use of CPAP to improve patient management and outcomes while reducing stress on the healthcare system. Additionally, understanding the extent to which OSA may be a risk factor for adverse COVID-19-related outcomes will help to inform proactive risk-mitigation strategies. I would also like to thank Philips for donating their high-quality CPAPs for this study.”

“The COVID-19 pandemic is creating tremendous demand for a limited number of mechanical ventilators, especially here in New York, and alternative approaches are needed to effectively manage patients with COVID-19 while reducing inpatient admissions and ventilation,” added Dr. Shah. “Prior investigation into the use of CPAP as an alternative to mechanical ventilation during viral pandemics have yielded promising results. The potential use of CPAP to delay or eliminate the need for hospitalization or ventilation during the current COVID-19 pandemic, in particular those with the additional burden of a sleep breathing disorder, would relieve significant pressure on our healthcare system while helping to achieve optimal patient outcomes.”

About Itamar Medical Ltd.

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.